Additionally, the transcription factor double homeobox 4 (DUX4) has been shown to block the IFNγ mediated upregulation of tsMHC-I in numerous cancer types in vitro resulting in failure to respond to anti-CTLA-4 and anti-PD-1 therapy and decreased overall survival (88). Here, DUX4 is linked to cancer.